Retrospective cohort study identifies SF3B4 and HMGB1 as significant predictors of mortality in gastric cancer, highlighting their clinical value.
Key Points
Elevated expression of SF3B4 and HMGB1 is linked to poor prognosis in gastric cancer patients, leading to shorter overall survival.
Combined analysis of SF3B4 and HMGB1 achieved an area under the curve of 0.914, indicating improved predictive performance for one-year outcomes.
Multivariate analysis revealed several independent factors associated with mortality, including high levels of SF3B4 and HMGB1 and advanced disease stage.
Results suggest potential for using SF3B4 and HMGB1 as biomarkers to stratify risk and guide clinical decision-making in gastric cancer.